Favipiravir

Biophore receives sub-license from MPP to manufacture and market molnupiravir for COVID treatment

Can market in India and 104 other countries Has also received DCGI regulatory license for Indian market Licenses applicable for…

3 years ago

Lupin Launches Favipiravir Drug Covihalt® for Treatment of Mild to Moderate COVID-19

Mumbai, August 05, 2020: Pharma major Lupin Limited (Lupin) today announced the launch of its Favipiravir in India under the…

4 years ago

Lasa & ICT explore Favipiravir therapy to fight COVID 19

Chennai, March 18, 2020: API major, Lasa Supergenerics Ltd In collaboration with the Institute of Chemical Technology (ICT) recently announced commencement for…

5 years ago